Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162513 | 1.00 | CYP3A4 (0.48) | CYP3A4IMPDH2NPC1RAB9AROCK2 | |
| SCHEMBL14124402 | 0.84 | IMPDH2 (0.64) | CYP3A4IMPDH2NPC1RAB9AROCK2 | |
| SCHEMBL20524931 | 0.83 | CYP3A4 (0.57) | CYP3A4IMPDH2NPC1RAB9AROCK2 | |
| SCHEMBL20524933 | 0.83 | CYP3A4 (0.57) | CYP3A4IMPDH2NPC1RAB9AROCK2 | |
| SCHEMBL2162380 | 0.80 | CYP3A4 (0.54) | CYP3A4IMPDH2NPC1RAB9AROCK2 | |
| SCHEMBL2162386 | 0.80 | CYP3A4 (0.54) | CYP3A4IMPDH2NPC1RAB9AROCK2 | |
| SCHEMBL20353542 | 0.80 | CYP3A4 (0.58) | CYP3A4IMPDH2NPC1RAB9ATRPV1 | |
| SCHEMBL14124381 | 0.78 | KDM4E (0.54) | CYP3A4IMPDH2NPC1RAB9ANAMPT | |
| SCHEMBL20353523 | 0.78 | CYP3A4 (0.56) | CYP3A4IMPDH2NPC1RAB9ACA12 | |
| SCHEMBL14124383 | 0.76 | CYP3A4 (0.61) | CYP3A4NPC1RAB9ATRPV1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899714-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160280656-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2016-09-29 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2008086269-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280656-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | CYP3A4 2672/4885IMPDH2 2131/4885NPC1 510/4885 |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | CYP3A4 2672/4885IMPDH2 2131/4885NPC1 510/4885 |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | CYP3A4 2672/4885IMPDH2 2131/4885NPC1 510/4885 |
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | CYP3A4 2672/4885IMPDH2 2131/4885NPC1 510/4885 |
| US-10899714-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | CYP3A4 2672/4885IMPDH2 2131/4885NPC1 510/4885 |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | CYP3A4 2672/4885IMPDH2 2131/4885NPC1 510/4885 |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | CYP3A4 2672/4885IMPDH2 2131/4885NPC1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.